Skip to Main Content

5,307

Views

13

CrossRef citations to date

0

Altmetric

Original Articles

Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma

Tong Lua Genentech, Inc, South San Francisco, CA, USACorrespondence[email protected]
View further author information

,

Leonid Gibianskyb QuantPharm LLC, North Potomac, MD, USAView further author information

,

Xiaobin Lia Genentech, Inc, South San Francisco, CA, USAView further author information

,

Chunze Lia Genentech, Inc, South San Francisco, CA, USAView further author information

,

Rong Shia Genentech, Inc, South San Francisco, CA, USAView further author information

,

Priya Agarwala Genentech, Inc, South San Francisco, CA, USAView further author information

,

Jamie Hirataa Genentech, Inc, South San Francisco, CA, USAView further author information

,

Dale Milesa Genentech, Inc, South San Francisco, CA, USAView further author information

,

Pascal Chanuc Genentech, Inc./F. Hoffmann-La Roche Ltd, Lyon, FranceView further author information

,

Sandhya Girisha Genentech, Inc, South San Francisco, CA, USAView further author information

,

Jin Yan Jina Genentech, Inc, South San Francisco, CA, USAView further author information

&

Dan Lua Genentech, Inc, South San Francisco, CA, USACorrespondence[email protected]
View further author information